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Background: Most studies addressing the volume–outcome relationship in complex surgical
procedures use hospital mortality as the sole outcome measure and are rarely based on de-
tailed clinical data. The lack of reliable information about comorbidities and tumor stages
makes the conclusions of these studies debatable.
The purpose of this study was to compare outcomes for esophageal resections for cancer in
low- versus high-volume hospitals, using an extensive set of variables concerning case-mix and
outcome measures, including long-term survival.
Methods: Clinical data, from 903 esophageal resections performed between January 1990
and December 1999, were retrieved from the original patients files. Three hundred and forty-
two patients were operated on in 11 low-volume hospitals (<7 resections/year) and 561 in a
single high-volume center.
Results: Mortality and morbidity rates were significantly lower in the high-volume center,
which had an in-hospital mortality of 5 vs 13% (P < .001). On multivariate analysis, hospital
volume, but also the presence of comorbidity proved to be strong prognostic factors predicting
in-hospital mortality (ORs 3.05 and 2.34). For stage I and II disease, there was a significantly
better 5-year survival in the high-volume center. (P = .04).
Conclusions: Hospital volume and comorbidity patterns are important determinants of
outcome in esophageal cancer surgery. Strong clinical endpoints such as in-hospital mortality
and survival can be used as performance indicators, only if they are joined by reliable case-mix
information.
Key Words: Esophageal cancer–Esophagectomy—Surgical outcomes—High-volume hospi-
tals—Case-mix—Comorbidity.
Since Luft published his study about the inverse
relationship between surgical volume and hospital
mortality in 1979, a plethora of studies has demon-
strated an improvement of clinical outcome with in-
creased hospital volume.1 Most of these studies use
hospital mortality as the sole outcome measure. Of-
ten, data are obtained from insurance companys
databases, and few studies use clinical data for risk-
adjustment.2
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The surgical treatment of esophageal cancer is of-
ten mentioned as one of the procedures for which
concentration in high-volume centers might improve
outcome.3,4 Nevertheless, a clear volume cut-off
point at which a cancer center is justified to perform
esophageal resections can hardly be defined.5,6 Also,
the volume–outcome literature for esophageal resec-
tions is limited to postoperative mortality as the sole
determinant of outcome.
Considering the growing evidence for this volume–
outcome relationship for esophageal cancer surgery,
we decided to investigate the outcome of these pro-
cedures in our region from 1990 until 1999. During
this study period none of the 11 hospitals affiliated
with the Comprehensive Cancer Center Leiden
(CCCL) in the Netherlands performed more than
seven esophageal resections a year; all are considered
low-volume hospitals (LVH).
In contrast to most volume–outcome studies, we
decided to use clinical data obtained from the original
patients files. We retrieved information about
comorbid diseases, tumor characteristics, treatment,
and outcome. Next to hospital mortality, several
determinants of outcome were examined, such as the
number of tumor-freemargins and complication rates.
Assuming that survival is an essential indicator for
quality in cancer surgery, we included a 5-year follow-
up. To put our data in the right perspective, we com-
pared these outcomes to the results of the topograph-
ically nearest high-volume referral center (HVH).
PATIENTS AND METHODS
All surgically treated esophageal carcinomas in the
period 1990–1999 were retrospectively identified
through the Leiden Cancer Registry (LCR) of the
Comprehensive Cancer Center Leiden (CCCL), in
which all cancer patients treated in the midwestern
part of the Netherlands are registered (1.7 million
inhabitants). All 11 hospitals gave consent to partic-
ipate in this audit and were visited by two investiga-
tors to retrieve the original patient files. Patient
demographics, pathological notes, data on the sur-
gical and (neo)adjuvant treatments, comorbidity as
well as postoperative morbidity, mortality, length of
stay, radicality of the resection, and long-term sur-
vival could all be retrieved from the patients files.
All tumors were staged according to the UICC
TNM classification of 1997. This was done by two
independent researchers. The obtained pTNM stages
were checked with the pTNM stages registered in the
LCR. Any discrepancies were discussed between the
researchers and a trained data manager from the
CCCL. If consensus could not be reached, the pTNM
stage was registered as ‘‘unknown.’’
To make a comparison with the outcomes of the
nearest high-volume center, data were categorized
according to the database of this center. In this hos-
pital, data of patients operated on for an esophageal
carcinoma are prospectively collected by a trained
data manager.
Differences in patient, tumor, and treatment char-
acteristics as well as outcome measurements were
assessed using the Kruskal–Wallis test for continuous
variables and the chi-square test for categorical
variables. Logistic regression was used to determine
prognostic factors of in-hospital mortality. Variables
were entered in the multivariate model as a prog-
nostic factor when P values <.10.
Survival was calculated as the difference between
date of surgery and either the date of death or the
date of last patient follow-up. For both groups, fol-
low-up of the patients was completed until December
31,, 2005. Observed survival rates were estimated by
using the Kaplan–Meier method. The log-rank test
was used to assess differences in survival between
patients who were operated in LVHs and the HVH.
All analyses were conducted using SPSS software
(version 12.0; SPSS Inc., Chicago. IL).
RESULTS
Hospital Volume
In 1990–1999 the evaluation and treatment of pa-
tients with an esophageal carcinoma were performed
in 11 hospitals in the region of the CCCL (one uni-
versity hospital, five teaching hospitals, and five
general hospitals). In 342 patients the tumor was re-
sected with curative intent. Figures 1A and B illus-
trate the distribution of surgical procedures within
the studied time period and between the different
hospitals. None of the CCCL hospitals performed
more than seven esophageal resections a year, which
makes them low-volume hospitals (LVHs).7 In the
same period, 561 esophageal resections were per-
formed in the nearest high-volume referral center
(HVH); a mean volume of 56 resections a year.
Patient, Tumor, and Treatment Characteristics
Table 1 shows the patient, tumor, and treatment
characteristics of both groups. More patients from the
HVHhad a squamous cell carcinoma and an advanced
stage of the disease. Operative strategy as well as
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adjuvant or neoadjuvant treatment varied widely be-
tween the groups. The vastmajority of resections in the
HVH was performed according to the transhiatal
technique, with a gastric tube reconstruction and
anastomosis to the cervical remnant esophagus. In the
LVH group a substantial number of anastomoses were
located in the thoracic cavity, after a (partial) gastro-
esophagectomy with either a gastric tube reconstruc-
tion or esophagojejunostomy. In the pathology,
clear surgical margins (R0) were reported in 72 % and
67 %, respectively for the LVHs and the HVH group.
Morbidity and Mortality
A significantly higher postoperative morbidity rate
was found in the LVH group, which probably is also
reflected by the longer hospital stay (Table 2). The
clinical anastomotic leakage rate differed between
both groups: LVHs 17% versus HVH 5%. The mor-
tality rate was almost three times higher for patients
treated in the LVHs than those who had their oper-
ation in the HVH: 13% vs 5%, respectively (P <
.001). None of the LVHs had a mortality rate lower
than the 5% of the HVH (Table 3). Univariate anal-
ysis showed that hospital volume, age, and comor-
bidity are prognostic factors for mortality (Table 4).
The mortality risk increased with higher age and the
number of organ systems affected. Especially cardiac
(OR 3.22, CI 1.91–5.44), vascular (OR 2.49, CI 1.45–
4.27), and respiratory (OR 1.90 CI 1.09–3.33)
comorbidity were risk factors for postoperative
mortality.
a
b
FIG. 1. (A) Number of esophageal resections per year in HVH versus LVH group (1990–1999). (B) Total number of esophageal resections
per hospital for HVH and LVHs (1990–1999).
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Multivariate analysis showed that both hospital
volume and comorbidity were independent prognos-
tic factors for hospital mortality (Table 5).
Survival
Figure 2 shows the crude 10-year overall survival
rate of all patients, in which an esophageal resection
for cancer was performed. Survival rates for patients
treated in the HVH are significantly better (P= .01).
This survival benefit loses its statistical significance,
after exclusion of patients who died postoperatively
of complications of the surgical procedure (Fig. 3).
Only, when we select patients with stage I and II
disease do we see a better survival in the HVH
(Fig. 4), meaning that its overall results are worsened
by the poor survival in the higher stages of the dis-
ease, stage III and IV. This can be explained by the
unfavorable tumor mix, with significantly more stage
IV disease treated in the HVH, than in the LVHs
(16.7 vs 6.1%).
TABLE 1. Patient, tumor, and treatment characteristics of
esophageal resections in LVHa and HVHb
Characteristics
LVH HVH
P value
No. of
patients %
No. of
patients %
Age (years) 65 64 .240
Range (years) 33–87 31–83
Gender .072
Male 249 73 438 78
Female 93 27 123 22
Comorbidity .078
No 142 42 273 49
1 organ system 111 32 179 32
2 organ systems 51 15 80 14
‡3 organ systems 11 3 27 5
Unknown 27 8 2 0
Histology .039
Adenocarcinoma 238 69 347 62
Squamous 96 28 193 34
Barretts dysplasia 4 1 6 1
Other 2 1 14 3
Unknown 2 1 1 0
Tumor localization .740
Cervical esophagus 7 2 14 3
Mid esophagus 53 15 86 15
Distal esophagus 114 33 204 36
Gastroesophageal junction 166 49 251 45
Unknown 2 1 6 1
Stage (pTNM) <.001
0 and I 43 12 61 11
II 162 47 214 38
III 107 31 186 33
IV 21 6 94 17
Unknown 9 3 6 1
(Neo)-adjuvant treatment <.001
None 316 92 464 83
Chemotherapy 17 5 93 17
Radiotherapy 0 0 2 0
Chemoradiation 4 1 0 0
Unknown 5 2 1 0
Surgical approach <.001
Abdomino-cervical 150 44 466 83
Thoraco-abdominal 97 28 60 11
Abdomino-thoraco-cervical 43 13 17 3
Abdominal 52 15 18 3
Anastomoses <.001
Cervical 195 57 541 96
Thoracic 91 27 8 2
Abdominal 56 16 8 2
Unknown 0 0 4 0
Total No. of patients 342 561
a LVH, low-volume hospitals.
b HVH, high-volume hospital.
TABLE 2. Outcome after resection of esophagus for cancer
in LVHa and HVHb
Outcome
LVH HVH
P value
No. of
patients %
No. of
patients %
Margins .93
R0 248 72 377 67
R1 55 16 161 28
R2 35 11 21 4
Unknown 4 1 2 1
Complications
Surgical complications 144 42 207 37 .01
General complications 191 56 207 37 <.001
No complications 89 26 247 44 <.001
Hospital stay
Median (days) 21 14 <.001
In-hospital
Mortality 45 13 28 5 <.001
Survival
Median (months) 21 22 .90
Range (months) (1–171) (1–158)
Total No. of patients 342 561
a LVH, low-volume hospitals.
b HVH, high-volume hospital.
TABLE 3. Mortality after resection of esophagus for cancer
in LVHa and HVHb
Hospitalsm
In-hospital mortality
No. of patients No. of deaths %
HVH 561 28 5.0
LVH 1 16 2 12.5
LVH 2 19 2 10.5
LVH 3 28 2 7.1
LVH 4 25 3 12.0
LVH 5 14 1 7.1
LVH 6 28 2 7.1
LVH 7 34 2 5.9
LVH 8 64 12 18.7
LVH 9 44 10 22.7
LVH 10 6 2 33.3
LVH 11 64 7 10.9
Total No. of patients 903 73 8
a LVH, low-volume hospitals.
b HVH, high-volume hospital.
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DISCUSSION
Currently, there is extensive interest in comparing
outcome of complex surgical procedures between
high- and low-volume providers. Most of the studies
are registry-based or relatively small. Our series offers
additional proof to the volume–outcome relation-
ship, because it is based on clinical data, retrieved
from the original patient files. This allows us to make
reliable comparisons for comorbidities and tumor
stage, which proved to be important prognostic fac-
tors for in-hospital mortality and survival.
A review of the evidence for a volume–outcome
relationship was published by Dudley in 20008 and
Halm in 2002.2 In the latter publication 135 studies
were reviewed, of which only five were not from the
United States or Canada. The majority of reports
TABLE 4. Univariate analysis of in-hospital mortality
Univariate analysis
OR 95% CI P value
Region <.001
HVH 1.00 Refa
LVH 2.88 1.76–4.72
Age (years) .01
<50 0.19 0.04–0.79
50–59 0.51 0.25–1.04
60–69 1.00 Refa
>70 1.20 0.70–2.04
Gender .20
Male 1.00 Refa
Female 0.67 0.36–1.24
Comorbidity <.001
No 1.00 Refa
1 organ system 2.02 1.06–3.86
2 organ systems 4.51 2.30–8.85
‡3 organ systems 4.97 1.92–12.83
Histology .97
Adenocarcinoma 1.00 Refa
Squamous 0.99 0.60–1.65
Stage .24
I 1.00 Refa
II 0.50 0.24–1.04
III 0.80 0.39–1.63
IV 0.65 0.26–1.61
Tumor localization .33
Cervical/mid esophagus 1.00 Refa
Distal esophagus/
gastroesophageal junction
1.41 0.71–2.80
Neoadjuvant treatment .14
No 1.00 Refa
Yes 0.49 0.20–1.25
Surgical approach .31
Transhiatal 1.00 Refa
Transthoracic 1.51 0.90–2.54 .12
Anastomosis .46
Cervical 1.00 Refa
Thoracic 1.52 0.77–3.01
Abdominal 1.26 0.52–3.04
a Ref, reference category.
TABLE 5. Multivariate analysis of in-hospital mortality
Multivariate analysis
OR 95% CI P value
Region <.001
HVH 1.00 Refa
LVHs 3.05 1.82–5.11
Age (years) .10
<50 0.22 0.05–0.96
50–59 0.60 0.29–1.25
60–69 1.00 Refa
>70 1.07 0.61–1.88
Comorbidity .004
No 1.00 Refa
Yes 2.34 1.30–4.19
a Ref, Reference category.
FIG. 2. Overall survival after esophagus resection for cancer:
LVHs vs HVH (in-hospital mortality included).
FIG. 3. Overall survival after esophagus resection for cancer:
LVHs vs HVH (in-hospital mortality excluded).
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were based on state or national hospital discharge
databases, where only a few studies used clinical data
for risk adjustment. The outcome measure was
‘‘death’’ in 79% of the studies, without analyzing
other dimensions of ‘‘outcome,’’ such as morbidity,
length of hospital stay, reoperations, et cetera. For
cancer-related procedures, long-term survival was not
mentioned. Higher-level methodological issues were
rarely addressed. Only five studies concerning cancer
treatment adjusted for (neo)-adjuvant therapies or
the type of surgical resection, but without any
adjustment for tumor stage.
Since 2002, more extensive studies on hospital or
surgeon volume appeared in the international litera-
ture. Birkmeyer reported a total number of 2.5 mil-
lion operations concerning 14 different surgical
procedures derived from the MEDICARE database.9
Mortality was the only outcome measure. Even after
risk adjustment, which decreased the outcome dif-
ferences between high- and low-volume hospitals, the
differences in results for esophageal and pancreatic
resections were highly significant, favoring surgery in
a high-volume center. Two more recently published
reviews of the volume–outcome relationship for
esophagectomies came up with 12 papers addressing
this subject.4,5 Only two of these studies were based
on clinical data. Although both showed a decrease in
mortality, they failed to show a statistically signifi-
cant relationship of operative mortality with hospital
volume.10,11 In our own review of the literature we
identified another study from the United Kingdom
using clinical data, in which hospital case volume
independently predicted operative mortality2 (Ta-
ble 6).
In the present study, independent data managers
collected data retrospectively from the patient files.
Not only the (in-hospital) mortality rate was ob-
tained, but also a range of other outcome data, such
as complication rates, resection margins, length of
stay, and long-term survival. In our opinion the latter
is an important performance indicator in surgical
oncology, surprisingly sporadically mentioned in the
volume–outcome literature.
The results of patients treated in 11 low-volume
hospitals were compared with the results of patients
treated in the nearest high-volume referral center.
Significant differences in outcome could be revealed.
In-hospital mortality was significantly higher in the
low-volume hospitals. The retrieved information
about comorbidity and stage of the disease made an
extensive preoperative risk and tumor load compar-
ison possible. Risk adjustment is an important issue
in outcome research, because patients with severe
comorbidity may be unequally distributed between
(groups of) hospitals. Especially, when only admin-
istrative data are used to assess hospital perfor-
mances, a selection-bias could lead to inadvertently
penalizing those surgeons who provide excellent care
to patients with more severe comorbid disease.7,13
Administrative data sets were never designed to pre-
dict risk and should probably not be used as such.14
Therefore, the validity of studies that fail to make
case-mix adjustments based on clinical data, has to be
questioned.
Nevertheless, a multivariate analysis of our data
shows hospital volume to be an independent prog-
nostic factor for in-hospital mortality. Although dif-
ferences in surgical technique could be detected, with
more transthoracic esophagectomies and intratho-
racic anastomoses in the low-volume group, these
factors are not significantly related to mortality.
These findings are confirmed by earlier reports.15–18
Also, there is little evidence for a beneficial role of
neoadjuvant therapies.19–22 However, above all,
choices made concerning diagnostic strategy, neoad-
juvant treatments, and surgical technique are related
to the knowledge, experience, and judgment of the
(team of) specialists.
After exclusion of in-hospital mortality, the sur-
vival of patients in the HVH was equal to those
treated in the LVHs. However, the results of the
HVH were negatively influenced by its case-mix.
More patients with stage IV disease were treated in
the HVH, corresponding with its status as a tertiary
referral center. The very poor survival in this group
of patients influences the overall results significantly.
Only when we are informed about differences in tu-
FIG. 4. Overall survival after esophagus resection for stage I and
II carcinoma: LVHs vs HVH (in-hospital mortality excluded).
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mor stage, we are able to detect real differences in
survival between patients treated in different hospi-
tals. Although in this study, all pathology reports
were reviewed, and the number of lymph nodes re-
sected was equal for both groups, we still have to be
cautious suggesting a survival benefit for high-volume
surgery. Only when a uniform pathologic evaluation
is guaranteed, can we be sure that observed differ-
ences in tumor stages are truly characteristic for pa-
tient groups. This could be the reason that few studies
have attempted to examine the influence of hospital
volume on long-term survival in cancer surgery, only
one of them concerning esophagectomies.23–27 A re-
cent study from the Netherlands failed to show a
survival benefit in high-volume hospitals (>20
resections a year), but did show an improved survival
for esophagectomies performed in university com-
pared to non-university hospitals.28 On the other
hand, for pancreatectomies and hepatectomies regis-
tered in the MEDICARE-database, Fong showed a
significantly better survival for procedures performed
in high-volume centers.25 In his study, administrative
data about age, gender, comorbidity, and extent of
the resection were included in a univariate and mul-
tivariate analysis, but stages of the disease, radicality,
and intent of the resection (palliative or curative)
were not reported.
In conclusion, our study shows that hospital vol-
ume is an important determinant of perioperative
morbidity and mortality in esophageal cancer sur-
gery. Nevertheless, volume in itself is no guarantee
for high quality of surgical care in a specific institu-
tion. Selecting (only) favorable patients can be the
basis of superior results. Therefore, case-mix adjust-
ments are essential in the assessment of surgical per-
formance of different institutions.
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